Monopar Therapeutics Inc (MNPR) FinancialsMNPRMonopar Therapeutics Inc

Evaluating the bottom line, Monopar Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.50%, provide a clear picture of how effectively MNPR converts its operational activities into shareholder value.

In the context of the broader market, MNPR competes directly with industry leaders such as NGNE and DRUG. With a market capitalization of $562.35M, it holds a leading position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against NGNE's N/A and DRUG's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The company has reported consistent net income losses, with Q2 2026 showing a loss of -5,313,300 USD, and the EPS for the same quarter at -0.62, reflecting ongoing financial struggles.